Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen ‘OGS-12’
- 1 November 2017
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 49-58
- https://doi.org/10.1016/j.ejca.2017.08.013
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Survival Trends and Long-Term Toxicity in Pediatric Patients with OsteosarcomaSarcoma, 2012
- The relation of tumour necrosis and survival in patients with osteosarcomaInternational Orthopaedics, 2011
- Frontline treatment of localized osteosarcoma without methotrexateCancer, 2011
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Does ifosfamide affect gonadal function?Pediatric Blood & Cancer, 2007
- SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patientsEuropean Journal of Cancer, 2007
- Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institutionEuropean Journal of Cancer, 2005
- Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological respondersEuropean Journal of Cancer, 2003
- Second malignant neoplasms in long‐term survivors of osteosarcomaCancer, 2002
- Neoadjuvante Therapie des lokalisierten Osteosarkoms der ExtremitätenKlinische Padiatrie, 1999